Metastatic breast cancer: an updating

Area of Science:

• Oncology
• Medical Research
• Cancer Therapy

Background:

• Metastatic breast cancer (MBC) management requires continuous innovation in detection and treatment.
• Current guidelines may not fully incorporate advanced follow-up strategies for early relapse detection.

Purpose of the Study:

• To review recent advancements in the detection, prognosis, and therapy of metastatic breast cancer.
• To highlight the role of targeted therapies and novel treatment approaches.

Main Methods:

• Review of recent literature on metastatic breast cancer.
• Analysis of data on prognostic factors, predictors of response, and therapeutic strategies.
• Examination of targeted therapies, including hormone therapy, immunotherapy, and monoclonal antibodies.

Main Results:

• Intensive post-operative follow-up with tumor marker panels can precede clinical signs of relapse.
• Estrogen receptor (ER) status, HER-2/neu expression, and specific biomarkers predict response to hormone therapy and chemotherapy.
• Novel therapies like aromatase inhibitors, trastuzumab, and bevacizumab show efficacy in specific patient populations.

Conclusions:

• Dynamic tumor marker evaluation aids in early detection of breast cancer relapse.
• Biomarkers such as ER, HER-2/neu, and others are crucial for predicting treatment response.
• Targeted therapies and innovative drug delivery systems represent significant progress in managing metastatic breast cancer.